<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESES: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is thought to be a key predictor for the development of Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>), a leading cause of morbidity and premature mortality in Europe </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is influenced by both genetic and lifestyle factors (e.g. <z:hpo ids='HP_0001513'>obesity</z:hpo> and physical inactivity) </plain></SENT>
<SENT sid="2" pm="."><plain>The RISC (Relationship between Insulin Sensitivity and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e>) Study is using the infrastructure of an extended European collaborative research group to study <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk in 1500 healthy people aged 30 to 60 years from 20 centres in 13 countries </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Baseline measurements of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance and insulin sensitivity are made by the oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test and the euglycaemic insulin clamp, respectively; carotid artery intima-medial thickness (by ultrasound), ankle/brachial pressure index and electrocardiography will enable evaluation of subclinical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> at baseline and at follow-up </plain></SENT>
<SENT sid="4" pm="."><plain>Classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors, as well as socioeconomic and lifestyle factors will be recorded at baseline; samples for measurement of biochemical and genetic markers will be collected and stored for future analyses </plain></SENT>
<SENT sid="5" pm="."><plain>Investigations will be repeated after 3 and 10 years to evaluate the relationship between <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and the development of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> as measured by carotid artery intima-media thickness </plain></SENT>
<SENT sid="6" pm="."><plain>Development of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and cardiovascular events are additional endpoints </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: This study will evaluate the importance of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:mp ids='MP_0002055'>diabetes</z:mp>, and has implications for the development of prevention and treatment strategies </plain></SENT>
</text></document>